| Symbol | PCSA |
|---|---|
| Name | PROCESSA PHARMACEUTICALS, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 7380 COCA COLA DRIVE,SUITE 106, HANOVER, Maryland, 21076, United States |
| Telephone | +1 443 776-3133 |
| Fax | — |
| — | |
| Website | https://www.processapharmaceuticals.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001533743 |
| Description | Processa Pharmaceuticals Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on the development of drug products that are intended to improve the survival and quality of life for patients who have an unmet medical need. The companys lead product, PCS499 is an oral tablet that is an analog of an active metabolite of an already approved drug. It focuses on fibrotic related diseases such as focal segmental glomerulosclerosis, idiopathic pulmonary fibrosis. Its pipeline products comprise PCS6422, PCS12852, and PCS100. Additional info from NASDAQ: |
Young David 🟢 acquired 2.1K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.22 Transaction Date: Jun 15, 2026 | Filing ID: 001414
Read moreSKIBSTED RUSSELL 🟢 acquired 2.7K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.22 Transaction Date: Jun 15, 2026 | Filing ID: 001412
Read moreNg George K 🟢 acquired 2.5K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.22 Transaction Date: Jun 15, 2026 | Filing ID: 001410
Read moreGuy Wendy 🟢 acquired 2.1K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.22 Transaction Date: Jun 15, 2026 | Filing ID: 001406
Read moreYoung David 🟢 acquired 1.8K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.57 Transaction Date: May 29, 2026 | Filing ID: 001295
Read moreSKIBSTED RUSSELL 🟢 acquired 2.3K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.57 Transaction Date: May 29, 2026 | Filing ID: 001293
Read moreNg George K 🟢 acquired 2.1K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.57 Transaction Date: May 29, 2026 | Filing ID: 001291
Read moreLin Patrick 🟢 acquired 1.6K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.57 Transaction Date: May 29, 2026 | Filing ID: 001289
Read moreGuy Wendy 🟢 acquired 1.8K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.57 Transaction Date: May 29, 2026 | Filing ID: 001287
Read moreNg George K 🟢 acquired 1.8K shares of Processa Pharmaceuticals, Inc. (PCSA) at $2.97 Transaction Date: May 15, 2026 | Filing ID: 001186
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT06536348 | PARKINSON BRASIL - Database on Motor and Non-Motor Aspects of Parkinson's Disea… | — | Parkinson Disease | Recruiting | 2025-01-01 | 2034-10-01 | ClinicalTrials.gov |
| NCT06568692 | A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metas… | Phase2 | Breast Cancer | Recruiting | 2024-10-02 | 2026-10-01 | ClinicalTrials.gov |
| NCT05270460 | Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With M… | Phase2 | Gastroparesis | Completed | 2022-03-09 | 2022-10-06 | ClinicalTrials.gov |
| NCT04861987 | A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patie… | Phase1 | Advanced Cancer | Completed | 2021-06-18 | 2024-09-09 | ClinicalTrials.gov |
| NCT04800562 | A Clinical Trial to Evaluate PCS499 in Treating Ulcerations in Patients Who Hav… | Phase2 | Necrobiosis Lipoidica | Terminated | 2021-04-12 | 2023-04-14 | ClinicalTrials.gov |
| NCT03698864 | A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of … | Phase2 | Necrobiosis Lipoidica | Completed | 2018-11-07 | 2020-02-25 | ClinicalTrials.gov |
| NCT03836222 | Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR … | Phase1 | Healthy | Completed | 2018-02-26 | 2018-06-04 | ClinicalTrials.gov |
| NCT03189914 | RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Ca… | Phase1 | Metastatic Pancreatic Cancer | Completed | 2017-10-02 | 2019-11-21 | ClinicalTrials.gov |
| NCT02030067 | Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignanc… | Phase1 | Solid Tumor | Completed | 2013-12-01 | 2019-12-01 | ClinicalTrials.gov |
| NCT01978366 | Open Label Extension Study of HT-100 in Patients With DMD | Phase2 | Duchenne Muscular Dystrophy | Terminated | 2013-10-01 | 2016-04-30 | ClinicalTrials.gov |
| NCT01847573 | Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of HT-1… | Phase1 | Duchenne Muscular Dystrophy | Terminated | 2013-05-01 | 2016-03-30 | ClinicalTrials.gov |
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PCS499 | Other | Phase PHASE2 | Necrobiosis Lipoidica | COMPLETED | NCT03698864 |
| Trental | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03836222 |
| PCS499 | Other | Phase PHASE1 | Healthy | COMPLETED | NCT03836222 |
| HT-100 | Other | Phase PHASE2 | Duchenne Muscular Dystrophy | TERMINATED | NCT01978366 |
| HT-100 | Other | Phase PHASE1 | Duchenne Muscular Dystrophy | TERMINATED | NCT01847573 |
| Placebo | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT05270460 |
| PCS12852 | Other | Phase PHASE2 | Gastroparesis | COMPLETED | NCT05270460 |
| placebo | Other | Phase PHASE2 | Necrobiosis Lipoidica | TERMINATED | NCT04800562 |
| PCS499 | Other | Phase PHASE2 | Necrobiosis Lipoidica | TERMINATED | NCT04800562 |
| RX-3117 | Other | Phase PHASE1 | Metastatic Pancreatic Cancer | COMPLETED | NCT03189914 |
| RX-3117 | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT02030067 |
| PCS6422 and capecitabine | Other | Phase PHASE1 | Advanced Cancer | COMPLETED | NCT04861987 |
| Capecitabine | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT06568692 |
| PCS6422 and capecitabine | Other | Phase PHASE2 | Breast Cancer | RECRUITING | NCT06568692 |